...Jun H. Choi; Mihir Shukla; Maher Abdul-Hay Background: Acute myeloid leukemia (AML) is a disease of the hematopoietic system that remains a therapeutic challenge despite advances in our understanding of the underlying cancer biology in the past decade. It is also an affliction of the elderly...

...Haihui Zhuang; Fenglin Li; Ting Si; Renzhi Pei; Mengxia Yu; Dong Chen; PeiPei Ye; Ying Lu Introduction: Recent studies have suggested that CD300A was an oncogene in acute myeloid leukemia (AML) development. However, the clinical relevance and biological insight into CD300A expression in AML...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 Allogeneic stem-cell transplantation Acute myeloid leukemia...

... of glomerulonephritis and acute myeloid leukemia have been reported in the literature. We describe the first case of a genetically diagnosed acute promyelocytic leukemia presenting with nephrotic range proteinuria that resolved with induction therapy with ATRA and ATO and performed a comprehensive review...

... or acute myeloid leukemia and grade 4 thrombocytopenia (<25 × 10 9 platelets/L). Approximately 30–65% of patients in this open-label extension phase experienced clinically relevant thrombocytopenic events; no conclusions could be made regarding long-term efficacy (non-randomized design, no placebo...

...Pasquale Niscola; Carla Mazzone; Stefano Fratoni; Nicolina Rita Ardu; Laura Cesini; Marco Giovannini; Tiziana Ottone; Lucia Anemona; Maria Teresa Voso; Paolo de Fabritiis We describe a case of acute myeloid leukemia with NPM1 mutation and disseminated leukemia cutis in a very old patient, who...

...Cecily Allen; Samir Gautam; Wei Cheng; Alexander B. Pine; Nikolai A. Podoltsev; Amer M Zeidan; Alfred I Lee; Rory M. Shallis Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) often receive antibacterial prophylaxis. Antibacterial agents can cause elevations...

...). Patients remained on active treatment for a median time of 357 days (range, 154–557 days). Most of our patients had a performance status of ECOG 2 or higher. Three patients had myelodysplastic syndromes, 7 patients had acute myeloid leukemia, and 2 patients had myelofibrosis. The median number...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2023 ETV6 MDS MPN Acute myeloid leukemia ETV6 is an ETS-family transcription factor with a helix-loop-helix domain encoded by the N-terminal exons and mediating...

...: RAS pathway mutations are common mechanisms of resistance to acute myeloid leukemia (AML) therapies. Trametinib, an oral MEK inhibitor, has been shown to have single-agent activity in relapsed/refractory AML and preclinical synergy with venetoclax. Methods: We conducted a single-center, open-label...

... of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Acute myeloid leukemia...

...Xin He; Yongfang Jiang; Xingbao Yu; Fei He; Haiyan Gao Introduction: The aim of the study was to construct a pyroptosis-related risk score (RS) model for the prognosis of acute myeloid leukemia (AML). Methods: The TARGET (training) and E-MTAB-1216 (validation) datasets were downloaded. Pyroptosis...

...Giulia Arrigo; Stefano D’Ardìa; Ernesta Audisio; Marco Cerrano; Roberto Freilone; Valentina Giai; Carolina Secreto; Irene Urbino; Chiara Frairia Extramedullary relapse of acute myeloid leukemia (AML) is not a rare event, and the FMS-like tyrosine kinase 3 ( FLT3 ) mutation is a well-known risk...

... or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Acute myeloid leukemia Allogeneic...

... or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Acute myeloid leukemia Relapse Neutropenia Cytarabine D-index High-dose...

..., and participate in many diseases, especially in cancer. Our previous study showed 1 altered circRNA named circ-anaphase promoting complex subunit 7 (ANAPC7) that was upregulated in acute myeloid leukemia (AML). To further clear the expression and clinical significance of circ-ANAPC7, we enlarged the sample size...

...Shinichiro Takahashi Differentiation therapy using all- trans retinoic acid (ATRA) is well established for the treatment of acute promyelocytic leukemia (APL). Several attempts have been made to treat non-APL acute myeloid leukemia (AML) patients by employing differentiation inducers...

... with hypomethylating agents (HMAs). Methods: We performed next-generation sequencing on bone marrow aspiration samples of 59 patients diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome with excess blasts-2, or chronic myelomonocytic leukemia and treated with decitabine or azacitidine as a frontline...

...Ivetta Danylesko; Jonathan Canaani; Avichai Shimoni; Joshua Fein; Noga Shem-Tov; Ronit Yerushalmi; Roni Shouval; Arnon Nagler Introduction: Achievement of an initial complete remission (CR) following induction chemotherapy is tightly correlated with survival in acute myeloid leukemia (AML) patients...

...Biao Wu; Zhengwei Jenny Mao; Zhi Wang; Pin Wu; Hongyu Huang; Wenjun Zhao; Lei Zhang; Zhou Zhang; Hongchao Yin; Robert Peter Gale; Bin Yin Resistance to cytarabine is an important cause of therapy failure in persons with acute myeloid leukemia (AML). Deoxycytidine kinase, encoded by DCK , catalyzes...